- Agilent Technologies ( NYSE: A ) has acquired Avida Biomed giving the diagnostics and applied chemicals company access to genomic tools that support cancer research.
- Agilent ( A ) said that Avida's products complement its own SureSelect portfolio and and advance its strategy to expand into clinical research and diagnostics markets. The company added that Avida's chemistries and assays work its automation platforms including Magnis and Bravo.
- In addition, Avida's technology will assist scientists with biomarker discovery, patient selection for clinical trials, diagnosis and prognosis, therapy selection, and disease recurrence.
- Financial details were not disclosed.
- See why Seeking Alpha contributor BOOX Research rates Agilent ( A ) a buy.
For further details see:
Agilent acquires Avida Biomed boosting next-generation sequencing for cancer research